SPRB
MaterialsSpruce Biosciences, Inc. Common Stock
Live · XNAS · May 9, Close
What's Moving SPRB Today?
No stock-specific AI insight has been generated for SPRB yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
SPRB News
20 articles- Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial OperationsYahoo Finance·May 4, 2026
- Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Apr 21, 2026
- Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Apr 20, 2026
- Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to TradeYahoo Finance·Apr 3, 2026
- Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?Yahoo Finance·Mar 18, 2026
- Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net LossYahoo Finance·Mar 17, 2026
- Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate UpdatesYahoo Finance·Mar 9, 2026
- Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial OfficerYahoo Finance·Mar 9, 2026
- Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayYahoo Finance·Mar 4, 2026
- Spruce Biosciences to Present at Upcoming Investor Conferences in MarchYahoo Finance·Mar 2, 2026
- Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer ConferenceMarketbeat·Mar 1, 2026
- Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)Yahoo Finance·Feb 18, 2026
- Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 17, 2026
- Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)Yahoo Finance·Feb 5, 2026
- Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership TeamYahoo Finance·Feb 3, 2026
- Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™Yahoo Finance·Jan 28, 2026
- Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic CollaborationYahoo Finance·Jan 19, 2026
- Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue CapitalYahoo Finance·Jan 8, 2026
- Spruce Biosciences initiated with an Outperform at OppenheimerYahoo Finance·Dec 24, 2025
- Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst callsYahoo Finance·Dec 23, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.